Cargando…

Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer

OBJECTIVE: Activating KRAS mutations are the most common drivers in the development of non-small cell lung cancer (NSCLC). However, unsuccess of treatment by direct inhibition of KRAS has been proven. Deregulation of PI3K signaling plays an important role in tumorigenesis and drug resistance in NSCL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yuxiang, Li, Xian, Liu, Xueling, Chen, Yi, Yang, Chunhao, Tan, Cun, Wang, Bobo, Sun, Yiming, Zhang, Xi, Gao, Yinglei, Ding, Jian, Meng, Linghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Chinese Anti-Cancer Association 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528459/ https://www.ncbi.nlm.nih.gov/pubmed/31119047 http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0361

Ejemplares similares

Erratum to Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer
por: Wang, Yuxiang, et al.
Publicado: (2019)

Genome‐wide gain‐of‐function screening identifies EZH2 mediating resistance to PI3Kα inhibitors in oesophageal squamous cell carcinoma
por: Xing, Hui, et al.
Publicado: (2022)

Intact regulation of G1/S transition renders esophageal squamous cell carcinoma sensitive to PI3Kα inhibitors
por: Zhang, Xu, et al.
Publicado: (2023)

Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines
por: Ma, Yixuan, et al.
Publicado: (2022)

Synergistic suppression of the PI3K inhibitor CAL-101 with bortezomib on mantle cell lymphoma growth
por: Qu, Fu-Lian, et al.
Publicado: (2015)

Combination of cetuximab and PP242 synergistically suppress the progression of wild-type KRAS colorectal carcinoma
por: Cheng, Lei, et al.
Publicado: (2015)

Targeting the PI3K signaling pathway in KRAS mutant colon cancer
por: Hong, Suntaek, et al.
Publicado: (2015)

Synergistic interactions with PI3K inhibition that induce apoptosis
por: Zwang, Yaara, et al.
Publicado: (2017)

Targeting Super‐Enhancers via Nanoparticle‐Facilitated BRD4 and CDK7 Inhibitors Synergistically Suppresses Pancreatic Ductal Adenocarcinoma
por: Huang, Chen‐Song, et al.
Publicado: (2020)

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2016)

Search for the suppressed decays $B^{+}\rightarrow K^{+}K^{+}\pi^{-}$ and $B^{+}\rightarrow \pi^{+}\pi^{+}K^{-}$
por: Aaij, Roel, et al.
Publicado: (2016)

Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor
por: Karimi, Leena, et al.
Publicado: (2023)

KRAS mutation‐independent downregulation of MAPK/PI3K signaling in colorectal cancer
por: Lam, Kuen Kuen, et al.
Publicado: (2022)

New Insights into PI3K Inhibitor Design using X-ray Structures of PI3Kα Complexed with a Potent Lead Compound
por: Yang, Xiuyan, et al.
Publicado: (2017)

Simultaneous suppression of PKM2 and PHGDH elicits synergistic anti-cancer effect in NSCLC
por: Wang, Kaixuan, et al.
Publicado: (2023)

Cyclin K goes with Cdk12 and Cdk13
por: Kohoutek, Jiri, et al.
Publicado: (2012)

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2016)

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2017)

Capsaicin suppresses breast cancer cell viability by regulating the CDK8/PI3K/Akt/Wnt/β-catenin signaling pathway
por: Wu, Di, et al.
Publicado: (2020)

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
por: Temraz, Sally, et al.
Publicado: (2015)

Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells()
por: Bonelli, Mara A., et al.
Publicado: (2017)

The doubly Cabibbo-suppressed decay $D^{+} \to K^{+}\pi^{-}\pi^{+}$
por: Aitala, E M, et al.
Publicado: (1997)

CDK1-PDK1-PI3K/Akt signaling pathway regulates embryonic and induced pluripotency
por: Wang, Xiao Qi, et al.
Publicado: (2017)

Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2018)

Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity
por: Chen, Zhenghu, et al.
Publicado: (2016)

Combined HASPIN and mTOR inhibition is synergistic against KRAS-driven carcinomas
por: Xu, Chenyue, et al.
Publicado: (2022)

Quadruple‐editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS‐mutated colorectal cancer cells
por: Wang, Zaozao, et al.
Publicado: (2021)

Cotargeting CHK1 and PI3K Synergistically Suppresses Tumor Growth of Oral Cavity Squamous Cell Carcinoma in Patient-Derived Xenografts
por: Yang, Chia-Yu, et al.
Publicado: (2020)

Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors
por: Polosukhina, Dina, et al.
Publicado: (2017)

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
por: Wang, Jieqiong, et al.
Publicado: (2016)

Dual inhibition of CDK4 and FYN leads to selective cell death in KRAS-mutant colorectal cancer
por: Wang, Yan, et al.
Publicado: (2019)

A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS
por: Zhang, Xiang-Hua, et al.
Publicado: (2013)

Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review
por: Nur Husna, Siti Muhamad, et al.
Publicado: (2018)

Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells
por: Litchfield, Lacey M., et al.
Publicado: (2020)

Insulin Stimulates PI3K/AKT and Cell Adhesion to Promote the Survival of Individualized Human Embryonic Stem Cells
por: Godoy‐Parejo, Carlos, et al.
Publicado: (2019)

Synergistic Effects of Targeted PI3K Signaling Inhibition and Chemotherapy in Liposarcoma
por: Guo, Shang, et al.
Publicado: (2014)

PI3Kα inhibitor impairs AKT phosphorylation and synergizes with novel angiogenesis inhibitor AL3810 in human hepatocellular carcinoma
por: Xie, Qin, et al.
Publicado: (2021)

Observation of the suppressed ADS modes $B^\pm \to [\pi^\pm K^\mp \pi^+\pi^-]_D K^\pm$ and $B^\pm \to [\pi^\pm K^\mp \pi^+\pi^-]_D \pi^\pm$
por: Aaij, R, et al.
Publicado: (2013)

PB1753: SYNERGISTIC ANTITUMOR EFFECT OF CHIDAMIDE WITH VENETOCLAX IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BY SUPPRESSING PI3K/AKT SIGNALING
por: Song, D., et al.
Publicado: (2022)

A Novel Small Molecule Antagonist of Choline Kinase-α That Simultaneously Suppresses MAPK and PI3K/AKT Signaling
por: Clem, Brian F., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_pmceo9vs168fi3r9icfimckllv